PT2705058T - Sequências de aminoácidos dirigidas contra il-17a, il-17f e/ou il17-a/f e polipéptidos compreendendo as mesmas - Google Patents
Sequências de aminoácidos dirigidas contra il-17a, il-17f e/ou il17-a/f e polipéptidos compreendendo as mesmasInfo
- Publication number
- PT2705058T PT2705058T PT127265932T PT12726593T PT2705058T PT 2705058 T PT2705058 T PT 2705058T PT 127265932 T PT127265932 T PT 127265932T PT 12726593 T PT12726593 T PT 12726593T PT 2705058 T PT2705058 T PT 2705058T
- Authority
- PT
- Portugal
- Prior art keywords
- polypeptides
- amino acid
- same
- acid sequences
- directed against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482802P | 2011-05-05 | 2011-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2705058T true PT2705058T (pt) | 2018-03-20 |
Family
ID=46245559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT127265932T PT2705058T (pt) | 2011-05-05 | 2012-05-04 | Sequências de aminoácidos dirigidas contra il-17a, il-17f e/ou il17-a/f e polipéptidos compreendendo as mesmas |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10017568B2 (https=) |
| EP (3) | EP4105231A1 (https=) |
| JP (5) | JP6628965B2 (https=) |
| KR (1) | KR102083230B1 (https=) |
| CN (2) | CN103717618B (https=) |
| AU (1) | AU2012257942B8 (https=) |
| BR (1) | BR112013028407B1 (https=) |
| CA (1) | CA2834907C (https=) |
| CL (1) | CL2013003090A1 (https=) |
| DK (1) | DK2705058T3 (https=) |
| EA (1) | EA035973B9 (https=) |
| ES (1) | ES2662371T3 (https=) |
| HR (1) | HRP20180380T1 (https=) |
| HU (1) | HUE037225T2 (https=) |
| IL (1) | IL228813B (https=) |
| LT (1) | LT2705058T (https=) |
| MX (1) | MX2013012844A (https=) |
| MY (1) | MY167231A (https=) |
| NZ (1) | NZ616761A (https=) |
| PH (1) | PH12013502234A1 (https=) |
| PT (1) | PT2705058T (https=) |
| SG (2) | SG10201606409TA (https=) |
| SI (1) | SI2705058T1 (https=) |
| UA (1) | UA117218C2 (https=) |
| WO (1) | WO2012156219A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102906118B (zh) | 2010-05-20 | 2017-07-28 | 埃博灵克斯股份有限公司 | 与her3相关的生物材料 |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| WO2014076321A1 (en) * | 2012-11-19 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| FR3007411B1 (fr) * | 2013-06-21 | 2015-07-03 | Agronomique Inst Nat Rech | Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations |
| JP2017507939A (ja) | 2014-02-21 | 2017-03-23 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用 |
| KR20250099289A (ko) | 2014-05-16 | 2025-07-01 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| PL3248986T3 (pl) | 2014-05-16 | 2022-05-16 | Ablynx Nv | Domeny zmienne immunoglobuliny |
| SG11201609274SA (en) * | 2014-05-22 | 2016-12-29 | Pieris Pharmaceuticals Gmbh | Novel specific-binding polypeptides and uses thereof |
| US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| RU2609627C2 (ru) * | 2014-09-26 | 2017-02-02 | Закрытое Акционерное Общество "Биокад" | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| GB201500463D0 (en) * | 2015-01-12 | 2015-02-25 | Cresendo Biolog Ltd | Therapeutic molecules |
| JP7001474B2 (ja) | 2015-01-21 | 2022-01-19 | インヒブルクス，インコーポレイティド | 非免疫原性単一ドメイン抗体 |
| WO2016123329A2 (en) | 2015-01-28 | 2016-08-04 | Genentech, Inc. | Gene expression markers and treatment of multiple sclerosis |
| MY206805A (en) * | 2015-10-27 | 2025-01-08 | UCB Biopharma SRL | Methods of treatment using anti-il-17a/f antibodies |
| GB201522391D0 (en) * | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibody molecules |
| RU2680011C2 (ru) * | 2016-04-29 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
| GB201612043D0 (en) | 2016-07-11 | 2016-08-24 | Crescendo Biologics Ltd | Composition for treatment of disorders |
| PE20191548A1 (es) | 2017-02-10 | 2019-10-24 | Genentech Inc | Anticuerpos contra triptasa, composiciones de estos y usos de estos |
| CN108359011B (zh) * | 2017-07-21 | 2019-06-25 | 华博生物医药技术（上海）有限公司 | 靶向于白介素17a的抗体、其制备方法和应用 |
| CN107857818A (zh) * | 2017-08-07 | 2018-03-30 | 上海科新生物技术股份有限公司 | 一种针对IL‑17和TNF‑α的双特异性融合蛋白 |
| CN111699003B (zh) * | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
| CN113603777B (zh) * | 2018-02-12 | 2022-10-21 | 原启生物科技(上海)有限责任公司 | Il17抗体及其应用 |
| CN110003329B (zh) * | 2019-04-12 | 2022-09-27 | 深圳普瑞金生物药业股份有限公司 | 多肽、il17a/f单域抗体、核苷酸序列及试剂盒 |
| WO2022012636A1 (en) * | 2020-07-15 | 2022-01-20 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric il17a and/or il17f |
| US20230416942A1 (en) * | 2020-08-21 | 2023-12-28 | Yale University | Nanobody Compositions and Methods of Use of the Same |
| WO2023035272A1 (zh) * | 2021-09-13 | 2023-03-16 | 深圳华普药物研发有限公司 | 一种il17抗体及其制备方法和应用 |
| CN117106083A (zh) * | 2022-03-25 | 2023-11-24 | 南京融捷康生物科技有限公司 | 一种抗il-17a的单域抗体及其用途 |
| WO2023186174A1 (en) * | 2022-04-01 | 2023-10-05 | Zai Lab (Shanghai) Co., Ltd. | Topical formulation comprising an il-17a binding molecule and uses thereof |
| WO2023203549A1 (en) | 2022-04-22 | 2023-10-26 | Moonlake Immunotherapeutics Ag | Methods of achieving safe and sustained control of il-17-dependent conditions in subjects responsive to treatment with an anti-il 17a/f nanobody |
| CN115093483B (zh) * | 2022-06-17 | 2025-06-03 | 国药中生生物技术研究院有限公司 | Il-17ra融合蛋白、药物组合物、注射剂及其应用 |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| EP4393948A1 (en) | 2022-12-28 | 2024-07-03 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Therapeutic vhh antibodies cross-neutralizing the il-17a and il-17f homodimers as well as the il-17af heterodimer |
| JP2026506075A (ja) | 2023-02-17 | 2026-02-20 | アブリンクス エン．ヴェー． | 新生児型ｆｃ受容体に結合するポリペプチド |
| CA3275145A1 (en) * | 2023-04-18 | 2024-10-24 | Moonlake Immunotherapeutics Ag | BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT DISEASES |
| CN116769027B (zh) * | 2023-06-09 | 2023-12-01 | 康元医疗科技(大连)有限公司 | 一种抗il-17纳米抗体、多肽及其应用 |
| TW202525846A (zh) | 2023-08-25 | 2025-07-01 | 美商普羅特歐拉吉克適美國公司 | 抗ｉｌ—１３多特異性抗體構築體及其用途 |
| CN120349412B (zh) * | 2023-12-21 | 2025-10-24 | 北京贝来生物科技有限公司 | 新型抗il-17a单域抗体、制备及其应用 |
| CN117843776B (zh) * | 2023-12-21 | 2024-08-30 | 北京贝来药业有限公司 | 抗体分子、核酸、制药用途及炎性疾病治疗方法 |
| CN120399065B (zh) * | 2023-12-21 | 2025-10-14 | 北京贝来药业有限公司 | 抗il-17a纳米抗体、药物组合物、方法及用途 |
| CN117843805B (zh) * | 2023-12-29 | 2024-09-06 | 北京贝来药业有限公司 | 抗体分子、核酸分子、药物组合物以及应用 |
| CN117843801B (zh) * | 2023-12-29 | 2024-08-02 | 北京贝来药业有限公司 | 以白介素家族成员为靶点的新型抗体以及下游产品 |
| CN117820481B (zh) * | 2023-12-29 | 2025-02-14 | 北京贝来药业有限公司 | 新型抗体分子及其制药用途 |
| CN117843804B (zh) * | 2023-12-29 | 2024-08-20 | 北京贝来药业有限公司 | 单域抗体串联分子及其序列、产品、制备和应用 |
| CN118206654B (zh) * | 2024-03-05 | 2024-09-20 | 北京贝来药业有限公司 | 用于疾病治疗的新型抗体及其产品和应用 |
| CN117866905B (zh) * | 2024-03-12 | 2024-06-04 | 北京贝来药业有限公司 | 基于纳米抗体基因修饰的干细胞及其制备方法和产品 |
| CN117866903B (zh) * | 2024-03-12 | 2024-06-04 | 北京贝来药业有限公司 | 单域抗体修饰的干细胞及其在疾病治疗中用途 |
| CN117866904B (zh) * | 2024-03-12 | 2024-06-07 | 北京贝来药业有限公司 | 基于单域抗体基因修饰的干细胞对于多种的疾病的制药用途 |
| CN117860786B (zh) * | 2024-03-12 | 2024-06-04 | 北京贝来药业有限公司 | 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途 |
Family Cites Families (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| AU675223B2 (en) | 1992-05-08 | 1997-01-30 | Creative Biomolecules, Inc. | Chimeric multivalent protein analogues and methods of use thereof |
| DE69334095T2 (de) | 1992-07-17 | 2007-04-12 | Dana-Farber Cancer Institute, Boston | Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| EP0702721B1 (en) | 1993-06-09 | 2001-01-03 | Unilever N.V. | Process for producing fusion proteins comprising scfv fragments by a transformed mould |
| US6562333B1 (en) | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
| US6274711B1 (en) | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
| US6091639A (en) | 1993-08-27 | 2000-07-18 | Kabushiki Kaisha Toshiba | Non-volatile semiconductor memory device and data programming method |
| WO1995022618A1 (en) | 1994-02-22 | 1995-08-24 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6902735B1 (en) | 1995-07-19 | 2005-06-07 | Genetics Institute, Llc | Antibodies to human IL-17F and other CTLA-8-related proteins |
| US6074849A (en) | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
| EP0839196B1 (en) | 1995-07-19 | 2005-05-11 | Genetics Institute, LLC | Human ctla-8 and uses of ctla-8-related proteins |
| AU7298398A (en) | 1996-11-19 | 1998-06-10 | Sangstat Medical Corporation | Enhanced effects for hapten conjugated therapeutics |
| US20020177188A1 (en) | 1998-05-15 | 2002-11-28 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| BR9813276A (pt) | 1997-10-27 | 2000-08-22 | Unilever Nv | Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma |
| WO1999037681A2 (en) | 1998-01-26 | 1999-07-29 | Unilever Plc | Method for producing antibody fragments |
| AU3295299A (en) * | 1998-02-19 | 1999-09-06 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
| US6486303B1 (en) | 1998-04-14 | 2002-11-26 | University Of Medicine & Dentistry Of New Jersey | Method for making hormone heterodimers |
| WO2000020593A1 (en) | 1998-10-02 | 2000-04-13 | Eli Lilly And Company | Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof |
| GB9824632D0 (en) | 1998-11-10 | 1999-01-06 | Celltech Therapeutics Ltd | Biological compounds |
| DE60013767T3 (de) | 1999-01-19 | 2009-07-09 | Unilever N.V. | Verfahren zur herstellung von antikörperfragmenten |
| EP1053751A1 (en) | 1999-05-17 | 2000-11-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions and methods for treating cell proliferation disorders |
| ES2379101T3 (es) | 1999-12-23 | 2012-04-20 | Genentech, Inc. | Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos |
| EP2180054A1 (en) | 1999-12-24 | 2010-04-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7943129B2 (en) | 2000-05-26 | 2011-05-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| WO2001090190A2 (en) | 2000-05-26 | 2001-11-29 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| US6741957B1 (en) | 2000-07-21 | 2004-05-25 | Daimlerchrysler Corporation | Analytical tire model for vehicle durability and ride comfort analysis |
| AU2002241922B2 (en) | 2001-01-17 | 2007-10-25 | Aptevo Research And Development Llc | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| AU2002242142A1 (en) | 2001-02-09 | 2002-08-28 | Johns Hopkins University | A cytokine related structurally to il-17 |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| AU2002355477B2 (en) | 2001-08-03 | 2008-09-25 | Medical Research Council | Method of identifying a consensus sequence for intracellular antibodies |
| EP1433793A4 (en) | 2001-09-13 | 2006-01-25 | Inst Antibodies Co Ltd | METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| KR100599789B1 (ko) | 2001-12-03 | 2006-07-12 | 삼성에스디아이 주식회사 | 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법 |
| EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| EP1456237A2 (en) | 2001-12-21 | 2004-09-15 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Method for cloning of variable domain sequences |
| WO2003055527A2 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
| ES2263984T3 (es) | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
| US20080241166A1 (en) | 2002-06-28 | 2008-10-02 | Domantis Limited | Ligands that bind a receptor |
| US7004940B2 (en) | 2002-10-10 | 2006-02-28 | Ethicon, Inc. | Devices for performing thermal ablation having movable ultrasound transducers |
| WO2004041867A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders |
| CA2505316C (en) | 2002-11-08 | 2014-08-05 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| US7993864B2 (en) | 2002-12-03 | 2011-08-09 | Ucb Pharma S.A. | Assay for identifying antibody producing cells |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| WO2004060965A2 (en) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| EP1587838B1 (en) | 2003-01-10 | 2015-04-15 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| CN1845938B (zh) | 2003-06-30 | 2010-05-26 | 杜门蒂斯有限公司 | 多肽 |
| PL2784084T5 (pl) | 2003-07-08 | 2024-12-02 | Novartis Pharma Ag | Przeciwciała antagonistyczne heterologicznych polipeptydów il-17a/f |
| AU2003264053A1 (en) | 2003-08-12 | 2005-03-10 | William M. Yarbrough | Treatment for acne vulgaris and method of use |
| ATE554390T1 (de) | 2003-08-20 | 2012-05-15 | Ucb Pharma Sa | Verfahren zur gewinnung von antikörpern |
| US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| US20050279676A1 (en) | 2004-06-21 | 2005-12-22 | Izzy Zuhair A | Fluid filter assembly for a dispensing faucet |
| US7882839B2 (en) | 2004-06-25 | 2011-02-08 | Ambis Jr Edward J | Custom mouthguard |
| US20060008601A1 (en) | 2004-06-25 | 2006-01-12 | Zeik Douglas B | Flexible laminate having an integrated pressure release valve |
| SI2311874T1 (sl) | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
| CN100396019C (zh) | 2004-07-31 | 2008-06-18 | 华为技术有限公司 | 移动终端数据源模拟方法 |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| WO2006040154A2 (en) | 2004-10-14 | 2006-04-20 | Dublin City University | Prokaryotic two hybrid system |
| GB0425569D0 (en) * | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| FR2879605B1 (fr) * | 2004-12-16 | 2008-10-17 | Centre Nat Rech Scient Cnrse | Production de formats d'anticorps et applications immunologiques de ces formats |
| MY142617A (en) | 2004-12-23 | 2010-12-15 | Domantis Ltd | Dual specific ligands with increased serum half-life |
| AU2005325801A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| CA2596509A1 (en) | 2005-02-14 | 2006-08-24 | Wyeth | Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor |
| WO2006122787A1 (en) | 2005-05-18 | 2006-11-23 | Ablynx Nv | Serum albumin binding proteins |
| ES2852423T3 (es) | 2005-05-20 | 2021-09-13 | Ablynx Nv | NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación |
| EP1934259A2 (en) | 2005-10-11 | 2008-06-25 | Ablynx N.V. | Nanobodies and polypeptides against egfr and igf-ir |
| US20090252681A1 (en) | 2005-10-11 | 2009-10-08 | Ablynx N.V. | Nanobodies and Polypeptides Against EGFR and IGF-IR |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| WO2007112940A2 (en) | 2006-03-31 | 2007-10-11 | Ablynx N.V. | Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same |
| EP2010568A1 (en) | 2006-04-14 | 2009-01-07 | Ablynx N.V. | Dp-78-like nanobodies |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| WO2008000279A1 (en) | 2006-06-26 | 2008-01-03 | Aida Centre, S.L. | Blister package integrating rfid based tags |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| CN101646689A (zh) | 2006-09-08 | 2010-02-10 | 埃博灵克斯股份有限公司 | 具有长半衰期的血清清蛋白结合蛋白 |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| WO2008043821A1 (en) | 2006-10-11 | 2008-04-17 | Ablynx N. V. | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof |
| GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| CA2671581A1 (en) | 2006-12-05 | 2008-06-12 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| SG178789A1 (en) | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| MX2009010273A (es) | 2007-03-26 | 2009-10-12 | Zymogenetics Inc | Proteinas de fusion il-17ra/rc solubles y metodos relacionados. |
| JP2010532764A (ja) | 2007-07-06 | 2010-10-14 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド |
| EP2220120A2 (en) | 2007-11-27 | 2010-08-25 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| US20110183861A1 (en) | 2008-01-29 | 2011-07-28 | Ablynn N.V. | Methods to stabilize proteins and polypeptides |
| EP2268668A1 (en) | 2008-04-17 | 2011-01-05 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| SG10201608871XA (en) | 2008-05-05 | 2016-12-29 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
| NZ589036A (en) | 2008-05-16 | 2012-07-27 | Ablynx Nv | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
| JP5581323B2 (ja) | 2008-09-29 | 2014-08-27 | ロシュ グリクアート アクチェンゲゼルシャフト | ヒトｉｌ１７に対する抗体およびその使用 |
| EP2403531A4 (en) | 2009-03-05 | 2013-02-27 | Abbott Lab | IL-17 BINDING PROTEINS |
| ES2551854T3 (es) | 2009-04-30 | 2015-11-24 | Ablynx N.V. | Procedimiento para la producción de anticuerpos de dominio |
| CA2759848C (en) | 2009-05-05 | 2018-12-04 | Novimmune S.A. | Anti-il-17f antibodies and methods of use thereof |
| WO2010142551A2 (en) * | 2009-06-12 | 2010-12-16 | Ablynx N.V. | Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family |
| WO2011053763A2 (en) | 2009-10-30 | 2011-05-05 | Centocor Ortho Biotech Inc. | Il-17a antagonists |
| HRP20171939T1 (hr) | 2010-01-15 | 2018-03-23 | Kirin-Amgen, Inc. | Formulacija protutijela i režimi terapije |
| US8965476B2 (en) * | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
| PH12013500660B1 (en) | 2010-10-08 | 2017-10-27 | Novartis Ag | Methods of treating psoriasis using il-17 antagonists |
| MX362591B (es) | 2010-11-05 | 2019-01-25 | Novartis Ag | Uso de antagonistas de il-17. |
| SG10201510762YA (en) | 2011-01-14 | 2016-01-28 | Ucb Pharma Sa | Antibody molecules which bind il-17a and il-17f |
| TWI439451B (zh) | 2011-03-24 | 2014-06-01 | Hoffmann La Roche | 雜環胺衍生物 |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| AU2012328917B2 (en) | 2011-10-24 | 2017-05-25 | Abbvie Inc. | Bispecific immunobinders directed against TNF and IL-17 |
| WO2013150043A1 (en) | 2012-04-05 | 2013-10-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| AR090626A1 (es) | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
| LT2953969T (lt) | 2013-02-08 | 2019-12-10 | Novartis Ag | Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui |
| CL2015001213A1 (es) | 2015-05-07 | 2015-07-10 | Pontificia Universidad Católica De Chile | Método ex vivo para predecir respuesta a un tratamiento inmunomodulador en pacientes con enfermedad inflamatoria, el cual comprende la cuantificación de las razones entre las concentraciones de citoquinas seleccionadas de ifn-gamma/il-17f, il17f/il-10, il-17f/ifn-gamma e il-10/il17f; y kit para llevar a cabo el método. |
-
2012
- 2012-04-05 UA UAA201314154A patent/UA117218C2/uk unknown
- 2012-05-04 SI SI201231255T patent/SI2705058T1/en unknown
- 2012-05-04 US US14/115,549 patent/US10017568B2/en active Active
- 2012-05-04 HR HRP20180380TT patent/HRP20180380T1/hr unknown
- 2012-05-04 SG SG10201606409TA patent/SG10201606409TA/en unknown
- 2012-05-04 HU HUE12726593A patent/HUE037225T2/hu unknown
- 2012-05-04 EP EP22169137.1A patent/EP4105231A1/en active Pending
- 2012-05-04 PT PT127265932T patent/PT2705058T/pt unknown
- 2012-05-04 DK DK12726593.2T patent/DK2705058T3/en active
- 2012-05-04 BR BR112013028407-2A patent/BR112013028407B1/pt active IP Right Grant
- 2012-05-04 EP EP18150770.8A patent/EP3363815A1/en active Pending
- 2012-05-04 NZ NZ616761A patent/NZ616761A/en unknown
- 2012-05-04 MY MYPI2013702070A patent/MY167231A/en unknown
- 2012-05-04 ES ES12726593.2T patent/ES2662371T3/es active Active
- 2012-05-04 CN CN201280033175.1A patent/CN103717618B/zh active Active
- 2012-05-04 JP JP2014508842A patent/JP6628965B2/ja active Active
- 2012-05-04 EP EP12726593.2A patent/EP2705058B1/en active Active
- 2012-05-04 CA CA2834907A patent/CA2834907C/en active Active
- 2012-05-04 SG SG2013079371A patent/SG194632A1/en unknown
- 2012-05-04 WO PCT/EP2012/058313 patent/WO2012156219A1/en not_active Ceased
- 2012-05-04 CN CN201611048984.6A patent/CN107098971B/zh active Active
- 2012-05-04 MX MX2013012844A patent/MX2013012844A/es unknown
- 2012-05-04 KR KR1020137032085A patent/KR102083230B1/ko active Active
- 2012-05-04 PH PH1/2013/502234A patent/PH12013502234A1/en unknown
- 2012-05-04 EA EA201391632A patent/EA035973B9/ru not_active IP Right Cessation
- 2012-05-04 LT LTEP12726593.2T patent/LT2705058T/lt unknown
- 2012-05-04 AU AU2012257942A patent/AU2012257942B8/en active Active
-
2013
- 2013-10-10 IL IL228813A patent/IL228813B/en active IP Right Grant
- 2013-10-25 CL CL2013003090A patent/CL2013003090A1/es unknown
-
2018
- 2018-05-02 JP JP2018088769A patent/JP6768027B2/ja active Active
- 2018-06-07 US US16/002,135 patent/US10829552B2/en active Active
-
2020
- 2020-05-14 JP JP2020084866A patent/JP7093380B2/ja active Active
- 2020-09-29 US US17/036,602 patent/US11773159B2/en active Active
-
2022
- 2022-02-24 US US17/679,675 patent/US20220195031A1/en active Pending
- 2022-06-17 JP JP2022097718A patent/JP2022137058A/ja active Pending
-
2024
- 2024-05-22 JP JP2024083267A patent/JP2024122989A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL228813A0 (en) | Amino acid sequences directed against a17-il, f17-il and/or f/a17-il and polypeptides containing them | |
| IL277891A (en) | Protein scaffolds based on type III fibronectin repeats with alternative binding surfaces | |
| GB201403126D0 (en) | Protein-containing adhesives, and manufacture and use thereof | |
| LT2753633T (lt) | Baltymo turintys klijai, jų gamyba ir panaudojimas | |
| IL237401B (en) | Modified amino acids containing an azido group | |
| LT2576661T (lt) | Baltymo turintys klijai, jų gamyba ir panaudojimas | |
| EP2611762A4 (en) | 1,3,3,3-TETRAFLUORPROPENE PROCESSAZEOTROPE WITH HF | |
| IL214971A0 (en) | Protein-containing foams, manufacture and use thereof | |
| EP3013789A4 (en) | Amino acid and peptide conjugates and conjugation process | |
| ZA201408990B (en) | Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof | |
| EP3023434A4 (en) | Polypeptide, dna molecule encoding the polypeptide, vector, preparation method and use | |
| ZA201307629B (en) | Reflector element and method and system for the production thereof | |
| HUP1000366A2 (en) | Novel proteins, their production process and use tereof | |
| IL219532A0 (en) | Frost free surfaces and method for manufacturing the same | |
| ZA201305485B (en) | Plant protein hydrolysates | |
| ZA201603274B (en) | Recombinant peptide vaccines against ticks, and nucleotide sequences coding for the recombinant peptides | |
| EP3040418A4 (en) | Production method for protein array or peptide array, identification method for functional protein or functional peptide, protein array or peptide array, and identification kit for functional protein or functional peptide | |
| PT2582810T (pt) | Ulvana liase, processo de fabrico e utilizações | |
| IL236027A0 (en) | A grenade, in particular a 40 mm grenade | |
| ZA201308273B (en) | Drought tolerance associated protein dt1 and coding sequence and application thereof | |
| AP4032A (en) | Hydrated n-fullerene amino acids, method for producing the latter, and pharmaceutical compositions on the basis thereof | |
| PL395686A1 (pl) | Nowy peptyd o wlasciwosciach hemocytotoksycznych, sposób jego wytwarzania i zastosowanie | |
| GB201113089D0 (en) | Protein hydrolysates | |
| GB201021389D0 (en) | Interferon 8 fusion protein | |
| GB201017841D0 (en) | The Hot One (Outdoor pursuits) |